沃达利单抗
Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279)
ChemLeader
Catalog No:
CAS No.:
MDLNo:
Formula:
MW:
Size
Quantity
- +
Product Overview
Product Name Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279)
CAS2329669-72-7
Storage condition Avoid repeated freeze-thaw. -80°C for one-year storage.
Security information
Product details

Vudalimab is a fully humanized bispecific antibody that potently inhibits both PD-1 and CTLA-4, key immune checkpoint receptors. It is designed to selectively activate tumor-targeting T cells, enhancing the immune response against cancer.

Related
Sorry, no related items
History
OST 577
Intetumumab
Tabalumab (Anti-TNFSF13B / BAFF / CD257)
Parsatuzumab (Anti-EGFL7)
Simtuzumab (Anti-LOXL2)
Anetumab (Anti-Mesothelin)
Anti-Human PD-1xCTLA-4 Bispecific Antibody(Vudalimab;XmAb-20717,cytotoxic T-lymphocyte-associated protein 4, CD152;programmed cell death 1, PD1, PD-1, CD279)
Urelumab (Anti-TNFRSF9 / 4-1BB / CD137)
Denintuzumab (Anti-CD19)
Diridavumab